Última actualización :
19/11/2024
Hormona   Vasopressin  
Inyectables
Estabilidad en solucion Estabilidad en mezcla Factores que influyen sobre la estabilidad Compatibilidades método de inyección Bibliografía pdf

Nombre comercial   Nombre comercial     

Los nombres comerciales son orientativos y los excipientes de la formulación pueden ser distintos dependiendo del país y del laboratorio fabricante.

Pressyn Canadá
Bibliografía   Inyectables   Bibliografía : Vasopressin  
Tipo Publicación
1057 periódico Cutie MR.
Compatibility of verapamil hydrochloride injection with commonly used additives.
Am J Hosp Pharm 1983 ; 40: 1205-1207.
1508 periódico Voirol P, Berger-Gryllaki M, Pannatier A, Eggimann P, Sadeghipour F.
Visual compatibility of insulin aspart with intravenous drugs frequently used in ICU.
EJHP 2015 ;22:123-124.
1611 periódico Chalmers JR, Bobek MB, Militello MA.
Visual compatibility of amiodarone hydrochloride injection with various intravenous drugs.
Am J Health-Syst Pharm 2001 ; 58: 504-506.
1801 periódico Feddema S, Rusho WJ, Tyler LS, Barker B.
Physical compatibility of vasopressin with medications commonly used in cardiac arrest.
Am J Health-Syst Pharm 2003 ; 60: 1271-1272.
1902 periódico Walker SE, Wyllie A, Law S.
Physical compatibility of pantoprazole with selected medications during simulated Y-site administration.
Can J Hosp Pharm 2004 ; 57, 2: 90-96.
1963 periódico Honisko ME, Fink JM, Militello MA, Mauro VF, Alexander KS.
Compatibility of argatroban with selected cardiovascular agents.
Am J Health-Syst Pharm 2004 ; 61: 2415-2418.
2017 periódico Barker B, Feddema S, Rusho WJ, Dengg R.
Visual compatibility of vasopressin with other injectable drugs.
Am J Health-Syst Pharm 2005 ; 62: 1969-1976.
2108 periódico Trusley C, Kupiec TC, Trissel LA.
Compatibility of micafungin injection with other drugs during simulated Y-site co-administration.
Int J Pharm Compound 2006 ; 10: 230-232.
2116 periódico Faria CE, Fiumara K, Patel N, Tran DC.
Visual compatibility of furosemide with phenylephrine and vasopressine.
Am J Health-Syst Pharm 2006 ; 63: 906-908.
2269 periódico Chan P, Bishop A, Kupiec TC, Trissel LA, Gole D, Jimidar IM, Vermeersch H.
Compatibility of ceftobiprole medocaril with selected drugs during simulated Y-site administration.
Am J Health-Syst Pharm 2008 ; 65, 16: 1545-1551.
3210 periódico Jasti Bhaskara R, Saraf Poonam.
Compatibility of Parenteral Furosemide with Seventeen Secondary Drugs Used in Standard Concentrations.
Int J Pharm Compound 2011 ; 15, 3: 259-261.
3249 periódico Singh BM, Dedhiya MG, Dinunzio J, Chan P, Kupiec TC, Trissel LA, Laudano JB.
Compatibility of ceftaroline fosamil for injection with selected drugs during simulated Y-site administration.
Am J Health-Syst Pharm 2011 ; 68: 2163-2169.
3254 periódico Housman S.T, Tessier P.R, Nicolau D.P, Kuti J.L.
Physical compatibility of telavancin hydrochloride with select i.v. drugs during simulated Y-site administration
Am J Health-Syst Pharm 2011 ; 68: 2265-2270.
3429 periódico Foushee J.A, Fox L.M, Gormley L.R, Lineberger M.S.
Physical compatibility of cisatracurium with selected drugs during simulated Y-site administration
Am J Health-Syst Pharm 2015 ; 72:483-486
3827 póster Ghazi I.M, Hamada Y, Nicolau D.P.
Compatibility of tedizolid phosphate with selected intravenous drugs via simulated Y-site conditions.
ASHP Midyear 2015
3828 póster Thabit A.K, Hamada Y, Nicolau D.P.
Ceftozolane/tazobactam physical compatibility during simulated Y-site administration.
ASHP Midyear 2015
3829 póster So W, Kim L, Thabit A.K, Nicolau D.P, Kuti J.L.
Compatibility of isavunazonium sulfate during simulated Y-site administration.
ASHP Midyear 2015
4055 periódico Monogue M, Almarzoky Abuhussain S, Kuti J, Nicolau D.
Physical compatibility of fosfomycin for injection with select i.v. drugs during simulated Y-site administration.
Am J Health-Syst Pharm 2018 , 75, 1:36-44
4145 periódico Asempa T.E, Avery L.M, Kidd J.M, Kuti J.L, Nicolau D.P.
Physical compatibility of plazomicin with select i.v. drugs during simulated Y-site administration.
Am J Health-Syst Pharm 2018 ;75,14:1048-1056
4389 periódico Côté K, Correal F, Metras M.E, Friciu M, Forest J.M, Leclair G.
Compatibilité physique des médicaments administrés en Y aux soins intensifs, en particulier la dexmédétomidine, le lévosimendan et la kétamine.
Pharmactuel 2019 ;52,4:206-213
4433 periódico Ghazi I.M, El Nekidy W.S, Sood A, Dulku A, Patel R, Patel K.
Y-site Administration of Imipenem/Cilastatin/ Relebactam With Common Intravenous Medications
Clin Ther 2020 ; 42, 3: 475-485.
4434 periódico Avery L.M, Chen, I.H, Reyes, S, Nicolau, D.P, Kuti J.L.
Assessment of the Physical Compatibility of Eravacycline and Common Parenteral Drugs During Simulated Y-site Administration.
Clin Ther 2019 ; 41, 10: 2162-2170.
4528 periódico Lu J, Liu Q, Kupiec T, Vail H, Lunch L, Fam D, Vu N.
Physical Compatibility of Cefiderocol with Selected Intravenous Drugs During Simulated Y-site Administration.
Int J Pharm Compound 2021 ;25,1:52-61
4569 periódico Lee T.M , Villareal C.L, Meyer L.M.
Y-Site Compatibility of Intravenous Levetiracetam With Commonly Used Critical Care Medications.
Hosp Pharm 2021 ; 56, 4: 282-286.
4570 periódico Greenhill K, Hornsby E, Gorman G.
Investigations of Physical Compatibilities of Commonly Used Intravenous Medications with and without Parenteral Nutrition in Pediatric Cardiovascular Intensive Care Unit Patients.
Pharmaceuticals 2019
4655 periódico Holyk A, Lindner A, Lindner S, Shippert B
Physical compatibility of Normosol-R with critical care medications used in patients with COVID-19 during simulated Y-site administration.
Am J Health-Syst Pharm 2022 ;79,1:27-33
4732 periódico Kenneally A, Agbana P, Gardner B, Bae Y, Mitchell T, Beckman E.
Compatibility of calcium chloride with milrinone, epinephrine, vasopressin, and heparin via in vitro testing and simulated Y-site administration.
Am J Health-Syst Pharm 2023 80, 3;164–170
4801 periódico Ruiz V, Yuwei Shen Y, Abouelhassan Y, Fouad A, Nicolau D, Kuti J.
Physical compatibility of sulbactam/durlobactam with select intravenous drugs during simulated Y-site administration.
Am J Health-Syst Pharm 2024 ;51,1:
4818 Laboratorio Giapreza 2.5mg per ml concentrate for solution for infusion - Summary of Product Characteristics Updated 30-Jun-2022
PAION UK Ltd 2022

  Mentions Légales